Original articleAssessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index
Section snippets
Data sources and study population
Danish nationwide registries can be linked at the individual level.17 The Danish National Patient Register18 contains information on in- and outpatient (ambulatory) hospital consultations according to the ICD classification. The Danish Registry of Medicinal Products Statistics19 records information on all pharmacy-dispensed medications according to the international Anatomical Therapeutic Chemical classification.
Medication dispensed during hospitalization or given directly from ambulatory
Results
A total of 10,738 adult patients with AD and 42,952 age- and sex-matched controls were analyzed (Table I). Higher proportions of patients with AD belonged to the highest socioeconomic class. About half of patients with AD had severe disease. The proportion of smokers was significantly higher among AD patients than among controls (11.2% vs 7.6%, P < .001). Tables II and III show the CCI scores for patients with AD and controls. Overall, AD patients had a significantly higher CCI score than
Discussion
We found significantly higher concurrences of major comorbidities in AD patients, and in particular among those with severe AD (possibly owing to systemic anti-AD treatment) and a history of smoking tobacco. AD is associated with impaired quality of life and psychiatric comorbidity.3, 4, 25, 26, 27 The link with autoimmune disease might partly be explained by overlapping genetic predispositions,5 but the AD-associated risk for rheumatoid arthritis and inflammatory bowel disease also might owe
References (31)
- et al.
Atopic dermatitis
Lancet
(2016) - et al.
Risk of developing major depressive disorder and anxiety disorders among adolescents and adults with atopic dermatitis: a nationwide longitudinal study
J Affect Disord
(2015) - et al.
Association between atopic dermatitis and depression in US adults
J Invest Dermatol
(2015) - et al.
Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes
JAllergy Clin Immunol
(2016) - et al.
Increasing comorbidities suggest that atopic dermatitis is a systemic disorder
J Invest Dermatol
(2017) - et al.
Eczema and cardiovascular risk factors in 2 US adult population studies
J Allergy Clin Immunol
(2015) - et al.
Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study
The Journal of Investigative Dermatology
(2016) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Lancet
(2007) - et al.
Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults
Journal of the American Academy of Dermatology
(2016)
Association of atopic dermatitis with smoking: a systematic review and meta-analysis
J Am Acad Dermatol
Is adult atopic eczema more common than we think? A population-based study in Danish adults
Acta dermato-venereologica
Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis
JAMA dermatology
Nonallergic comorbidities of atopic eczema: an overview of systematic reviews
Allergy
Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies
Allergy
Cited by (0)
Funding sources: None.
Conflicts of interest: Dr Thyssen is supported by an unrestricted grant from the Lundbeck Foundation and has attended advisory board meetings for Roche and Sanofi-Genzyme. Dr Skov has received consultancy and speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and Leo Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly, Celgene, and Novartis. Dr Hamann has no relevant conflicts of interest to declare. Dr Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation. Dr Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria for consulting and speaking for Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals.
Reprints not available from the authors.